Surfing MASH’s Post

Important study on medication review in the emergency department

🎉I’m officially an author! Really happy (and proud!!) to share that the study I contributed to during my masters finally is published✅ A huge thanks to my co-author Ingeborg Hjalland Ulla, and our fantastic supervisors Marianne Lea and Liv Mathiesen. It has been a pleasure working with this dream-team🤝🏼🌟 Here are some key-findings🔑 💊Among the 250 included patients, 80% had one or more medication discrepancies (MDs). 👵🏼The risk of MDs increased with increasing age, increasing number of medications, and the use of multidose drug dispensing. 🏥The potential clinical relevance of the MDs seems less severe compared to a similar Norwegian study from 2011, which can indicate an improvement in Norwegian hospitals. Check out the article to learn more🔍 #clinicalpharmacy #medicationreconciliation #medicationdiscrepancies #patientsafety #norwegianhospitals #medicationerrors

This study compares prioritisation algorithms for the selection of patients for medication reviews in the emergency department. Identifies that further research should focus on how clinical algorithms affect the selection of patients and on the importance of the reviews carried out by pharmacists. Derek Stewart European Society of Clinical Pharmacy (ESCP) Yolande Hanssens Vibhu Paudyal Shusen Sun Filipa Alves da Costa Anna Birna Almarsdóttir #pharmacy #pharmacists #pharmacylife #clinicalpharmacy #pharmaceuticalcare #pharmacycollege #pharmacystudents #pharmacytechnicians https://lnkd.in/dDPjuwQW

Have a look at this important study on medication review in the emergency department. Is this relevant to your practice or research? Please like, comment and repost.

Merck Healthcare, a leading science and technology company, and the Pediatric Praziquantel Consortium today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel for the treatment of schistosomiasis in children aged 3 months to 6 years. The application was submitted by Merck, on behalf of the Consortium, under the EU-M4all procedure for high-priority medicines for human use intended for countries outside the European Union. “With this positive response by EMA, a critical milestone was achieved to broaden the range of options for the treatment of schistosomiasis so as to address the needs of millions of preschool-aged children”, said Peter Guenter, Member of the Executive Board and CEO of Healthcare at Merck. “I thank all partners of the Pediatric Praziquantel Consortium for this achievement and for the continuous collaboration. Together, we strive to contribute to the elimination of schistosomiasis as a public health problem by 2030, as part of our commitment to drive health equity through our innovations and products.” Arpraziquantel is derived from praziquantel, the standard of care treatment of schistosomiasis developed in the 1970s. Extending the range of options for the treatment of schistosomiasis, arpraziquantel is tailored for use in preschool-aged children. The tablet is administered by dissolving it in water and has an improved taste to make it more palatable for very young children. In addition, the 150mg tablet has been specifically designed to withstand the hot and humid conditions presented by a tropical climate. The positive CHMP scientific opinion by EMA is the basis for a potential inclusion of arpraziquantel in the World Health Organization’s list of prequalified and essential medicinal products. Together with the positive scientific opinion, the planned prequalification will support the regulatory pathway in African countries. #schistosomiasis #Arpraziquantel #PediatricPraziquantelConsortium #MerckGroup #MerckHealthcare #Merck 👉 Arpraziquantel EMA Response | Merck (merckgroup.com)

During its annual #scientific #meeting, the SA Heart Association met with members of the National Department of #Health, Council for Medical Schemes, SA Medical Association, #medicalaid industry, #pharmaceutical and #medicaldevice industry, as well as the Global Heart Hub with the intention to develop an #advocacyforum to create a more empowered and engaged community of #patients living with #cardiovasculardisease.

⚠️Shortage of vigabatrin (Sabril) tablets⚠️ Sanofi-Aventis has notified the TGA about a shortage of the tablet form of their vigabatrin product, Sabril. The shortage was triggered by a global recall and is expected to last until 30 September 2023. The oral 500 mg powder sachet form of the product was also recalled, but unaffected stock is now available. Vigabatrin is used to treat adults and children living with serious epileptic conditions that aren’t controlled satisfactorily by other medicines. We are working with Sanofi-Aventis and the specialist health professionals who prescribe vigabatrin to limit the impact of this shortage on patients. We anticipate that the available powder sachet form of Sabril will cover patients’ needs until the tablets are available again. The TGA has also formed a medicine shortages action group (MSAG), including representatives from the Epilepsy Society of Australia, Australian Medical Association, Pharmaceutical Society of Australia, The Society of Hospital Pharmacists of Australia, Pharmacy Guild of Australia, The Royal Australian College of General Practitioners (RACGP) and specialist health professionals from the Queensland Children’s Hospital, Sydney Children’s Hospital and Royal Adelaide Hospital/The Queen Elizabeth Hospital. The MSAG has developed advice for patients, carers, clinicians and pharmacists. Find out more: https://lnkd.in/g2VVygW7

📢 Exciting News for CIDP Patients! I'm happy to hear the news that offers a new treatment option for those living with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Working with PTCE, I've learned so much about CIDP by collaborating with expert clinicians, understanding medication challenges from pharmacists and nurses, and even had the privilege of talking to a couple fantastic patient advocates. Their stories highlight the need for effective treatments. On Friday, argenx announced the FDA approval of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), a neonatal Fc receptor (FcRn) blocker. This is the first new treatment mechanism in over 30 years, offering hope and a new option for patients. Efgartigimod alfa and hyaluronidase-qvfc showed significant improvements in mobility, function, and strength in clinical trials. Let's celebrate this monumental step forward in CIDP treatment! #CIDP #PatientCare #NewTreatment #FDAApproval #efgartigimod #argenx #HealthcareInnovation #PTCE